User: Guest  Login
Document type:
journal article 
Author(s):
Harbeck, Nadia; Saupe, Steffen; Jäger, Elke; Schmidt, Marcus; Kreienberg, Rolf; Müller, Lothar; Otremba, Burkhard Joerg; Waldenmaier, Dirk; Dorn, Julia; Warm, Mathias; Scholz, Michael; Untch, Michael; de Wit, Maike; Barinoff, Jana; Lück, Hans-Joachim; Harter, Philipp; Augustin, Doris; Harnett, Paul; Beckmann, Matthias W; Al-Batran, Salah-Eddin; PELICAN Investigators 
Title:
A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study. 
Abstract:
The PELICAN trial evaluates for the first time efficacy and safety of pegylated liposomal doxorubicin (PLD) versus capecitabine as first-line treatment of metastatic breast cancer (MBC).This randomized, phase III, open-label, multicenter trial enrolled first-line MBC patients who were ineligible for endocrine or trastuzumab therapy. Cumulative adjuvant anthracyclines of 360 mg/m doxorubicin or equivalent were allowed. Left ventricular ejection fraction of>50 % was required. Patients received PLD...    »
 
Journal title abbreviation:
Breast Cancer Res Treat 
Year:
2017 
Journal volume:
161 
Journal issue:
Pages contribution:
63-72 
Language:
eng 
Print-ISSN:
0167-6806 
TUM Institution:
Klinik und Poliklinik für Frauenheilkunde